229 related articles for article (PubMed ID: 15195111)
1. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.
Begum S; Rosenbaum E; Henrique R; Cohen Y; Sidransky D; Westra WH
Mod Pathol; 2004 Nov; 17(11):1359-63. PubMed ID: 15195111
[TBL] [Abstract][Full Text] [Related]
2. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma.
Rosenbaum E; Hosler G; Zahurak M; Cohen Y; Sidransky D; Westra WH
Mod Pathol; 2005 Jul; 18(7):898-902. PubMed ID: 15968271
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
Takano T; Ito Y; Hirokawa M; Yoshida H; Miyauchi A
Br J Cancer; 2007 May; 96(10):1549-53. PubMed ID: 17453004
[TBL] [Abstract][Full Text] [Related]
4. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
6. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
8. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Nikiforova MN; Kimura ET; Gandhi M; Biddinger PW; Knauf JA; Basolo F; Zhu Z; Giannini R; Salvatore G; Fusco A; Santoro M; Fagin JA; Nikiforov YE
J Clin Endocrinol Metab; 2003 Nov; 88(11):5399-404. PubMed ID: 14602780
[TBL] [Abstract][Full Text] [Related]
10. Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures.
Cracolici V; Mujacic I; Kadri S; Alikhan M; Niu N; Segal JP; Rosen LE; Sarne DH; Morgan A; Desouky S; Cipriani NA
Endocr Pathol; 2018 Mar; 29(1):9-14. PubMed ID: 28710706
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
Jakubowski M; Hunt JL
Am J Surg Pathol; 2009 Nov; 33(11):1590-3. PubMed ID: 19738460
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
14. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
Nikiforov YE
Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
[TBL] [Abstract][Full Text] [Related]
16. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
17. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
Walts AE; Pao A; Sacks W; Bose S
Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
19. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features.
Cho U; Mete O; Kim MH; Bae JS; Jung CK
Mod Pathol; 2017 Jun; 30(6):810-825. PubMed ID: 28281551
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]